Peter M. Strumph
Direktor/Vorstandsmitglied bei Amygdala Neurosciences, Inc.
Aktive Positionen von Peter M. Strumph
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Amygdala Neurosciences, Inc.
Amygdala Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Amygdala Neurosciences, Inc. is a biopharmaceutical company. The firm focuses on improving public health by developing and commercializing therapy to treat substance use disorders. Its development programs include treatment and prevention of opioid, nicotine, alcohol and cocaine use disorders. The company was founded by Lou Lange, Ivan Diamond, Peter Strumph, Brent Blackburn, and Adrienne MacMillan in 2015 and is headquartered in San Francisco, CA. | Direktor/Vorstandsmitglied | 01.01.2016 | - |
Vorstandsvorsitzender | 01.01.2015 | - | |
Gründer | 01.01.2015 | - | |
Präsident | 01.01.2015 | - |
Karriereverlauf von Peter M. Strumph
Ehemalige bekannte Positionen von Peter M. Strumph
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CODEXIS, INC. | Vorstandsvorsitzender | 20.02.2012 | 22.02.2012 |
Corporate Officer/Principal | 29.06.2010 | 20.02.2012 | |
Präsident | 28.06.2010 | 13.06.2012 | |
CAPRICOR THERAPEUTICS, INC. | Präsident | 01.09.2007 | 10.06.2009 |
Nile Therapeutics, Inc. /Old/ | Präsident | 17.06.1996 | 11.10.2007 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Geschäftsführer | 01.01.1997 | 01.01.2007 |
PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.04.2013 | - |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Ausbildung von Peter M. Strumph
The Wharton School of the University of Pennsylvania | Masters Business Admin |
University of Pennsylvania | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Operativ
President | 4 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 2 |
Sektoral
Health Technology | 7 |
Consumer Services | 3 |
Process Industries | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
CAPRICOR THERAPEUTICS, INC. | Health Technology |
CODEXIS, INC. | Process Industries |
Private Unternehmen | 5 |
---|---|
Nile Therapeutics, Inc. /Old/ | Health Technology |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Portola Pharmaceuticals LLC
Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Amygdala Neurosciences, Inc.
Amygdala Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Amygdala Neurosciences, Inc. is a biopharmaceutical company. The firm focuses on improving public health by developing and commercializing therapy to treat substance use disorders. Its development programs include treatment and prevention of opioid, nicotine, alcohol and cocaine use disorders. The company was founded by Lou Lange, Ivan Diamond, Peter Strumph, Brent Blackburn, and Adrienne MacMillan in 2015 and is headquartered in San Francisco, CA. | Health Technology |
- Börse
- Insiders
- Peter M. Strumph
- Erfahrung